Hitoshi Takahashi

Hitoshi Takahashi

Auto-generated profile, based on publicly available information

Hitoshi Takahashi

Niigata University

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2005 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
AIAtsushi Ishikawa
Atsushi Ishikawa
YPYue‐Shan Piao
Yue‐Shan Piao
AMAkinori Miyashita
Akinori Miyashita
RKRyozo Kuwano
Ryozo Kuwano
OOOsamu Onodera
Osamu Onodera
HTHitoshi Takahashi
Hitoshi Takahashi

10 August 2011 in Acta Neuropathologica
Verified
Journal Article
Closed access
PDF file
YTYasuko Toyoshima
Yasuko Toyoshima
HTHajime Tanaka
Hajime Tanaka
MSMitsuteru Shimohata
Mitsuteru Shimohata
KKKakuhei Kimura
Kakuhei Kimura
TMTakashi Morita
Takashi Morita
HTHitoshi Takahashi
Hitoshi Takahashi

23 February 2013 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
HTHirotaka Tanaka
Hirotaka Tanaka
MSMasamitsu Shimazawa
Masamitsu Shimazawa
MTMasafumi Takata
Masafumi Takata
HKHideo Kaneko
Hideo Kaneko
KTKazuhiro Tsuruma
Kazuhiro Tsuruma
HHHideaki Hara
Hideaki Hara

16 November 2011 in American Journal of Medical Genetics Part B: Neuropsychiatric Genetics
Verified
Journal Article
Closed access
PDF file
YHYasue Horiuchi
Yasue Horiuchi
SISyuhei Iida
Syuhei Iida
MKMinori Koga
Minori Koga
HIHiroki Ishiguro
Hiroki Ishiguro
YIYoshimi Iijima
Yoshimi Iijima
TATadao Arinami
Tadao Arinami

1 January 2019 in Neurologia medico-chirurgica
Verified
Journal Article
Open access
PDF file
TNTakanori Nozawa
Takanori Nozawa
MOMasayasu Okada
Masayasu Okada
MNManabu Natsumeda
Manabu Natsumeda
TETakeyoshi Eda
Takeyoshi Eda
HAHideaki Abe
Hideaki Abe
AKAkiyoshi Kakita
Akiyoshi Kakita
Epidermal growth factor receptor variant III (EGFRvIII) is a tumor-specific cell surface antigen often expressed in glioblastoma and has drawn much attention as a possible therapeutic target. We performed immunohistochemistry on histology sections of surgical specimens taken from 67 cases with glioblastoma, isocitrate dehydrogenase-wild type, and evaluated the morphological characteristics and distribution of the EGFRvIII-positive tumor cells. We then evaluated the localization of EGFRvIII-expression within the tumor and peritumoral areas. EGFRvIII immunopositivity was detected in 15 specimens taken from 13 patients, including two recurrent specimens taken from the same patient at relapse. Immunofluorescence staining demonstrated that EGFRvIII-positive cells were present in cells positive for glial fibrillary acidic protein (GFAP), and some showed astrocytic differentiation with multiple fine processes and others did not shown. The EGFRvIII-positive cells were located in cellular areas of the tumor, but not in the invading zone. In the two recurrent cases, EGFRvIII-positive cells were markedly decreased in one case and retained in the other. With regard to overall survival, univariate analysis indicated that EGFRvIII-expression in patients with glioblastoma was not significantly associated with a favorable outcome. Double-labeling immunofluorescence staining of EGFRvIII and GFAP showed that processes of large, well differentiated, GFAP-positive glia extend to and surround less differentiated, EGFRvIII-positive glial cells in cellular areas of tumor. However, in the tumor periphery, EGFRvIII-positive tumor cells were not observed. This finding suggests that EGFRvIII is involved in tumor proliferation, but that invading glioma cells lose their EGFRvIII expression.

11 November 2009 in Neuropathology
Verified
Journal Article
Closed access
PDF file
HSHiroshi Shimizu
Hiroshi Shimizu
MYMitsunori Yamada
Mitsunori Yamada
NMNae Matsubara
Nae Matsubara
HTHiroki Takano
Hiroki Takano
YUYoshitaka Umeda
Yoshitaka Umeda
HTHitoshi Takahashi
Hitoshi Takahashi